ECTRIMS 2016: What Future For Merck KGaA’s Cladribine?
Executive Summary
With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA is using ECTRIMS 2016 as the stage for numerous new presentations on the drug’s efficacy and safety. Data on this additional induction therapy are positive but regulators and the market could prove difficult to persuade.
You may also be interested in...
Apitope Upbeat After Merck Returns Multiple Sclerosis Candidate
With cladribine battling it out again with regulatory authorities for approval in multiple sclerosis, Merck decides to hand back rights to Apitope's Phase II MS drug candidate.
Merck KGaA Previews Cladribine Regulatory Revival Story At ECTRIMS
With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA uses ECTRIMS 2016 to showcase longer-term efficacy data and a safety analysis that could lay to rest concerns about the multiple sclerosis therapy's risk of malignancy.
ECTRIMS 2016: What Future For Merck KGaA’s Cladribine?
With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA is using ECTRIMS 2016 as the stage for numerous new presentations on the drug’s efficacy and safety. Data on this additional induction therapy are positive, but regulators and the market could prove difficult to persuade.